PubMed Health⌕ Search

Biomedical subjects

F Bosc

Publications and source records attributed to F Bosc.

8 recordsLinked to original sources
PubMed1990

[The bioequivalence of two injectable solutions of spiramycin in young cattle].

A bioequivalence study was performed in 12 young cattle in order to compare 2 injectable solutions of spiramycin containing 60 M IU/100 ml (Suanovil 20) and 100 M IU/100 ml, respectively. In a cross-over design, a single dose of 100,000 IU/kg bw was administered intramuscularly, allowing 8 d between the 2 administrations. For each formulation, the following parameters were determined: maximum serum concentration (Cmax) and time to reach peak concentration (Tmax), mean residence time (MRT), area under the time-concentration curve (AUC), half-life (t1/2 beta). Statistical analysis of t1/2 beta, Tmax (Wilcoxon's test) and Cmax, MRT, AUC (ANOVA), indicated no significant differnces between the two formulations (P greater than 0.05). Westlake's confidence intervals calculated for a 95% probability were 23.1% for Cmax, 11.1% for MRT and 13.2% for AUC, respectively, which confirmed the bioequivalence of the 2 formulations. It must be noted that an experimental design using 12 animals is generally insufficient to demonstrate bioequivalence, according to the recommended statistical criteria.

Absorption↗
PubMed1984

[Inhibition by a 2-pyridyltetrahydrothiophene derivative (40749 RP) of gastric secretion stimulated by pentagastrin. Results in 30 duodenal ulcer patients].

The aim of this study was to investigate the effects of a new antisecretory compound (40749 RP) on the pentagastrin stimulated gastric secretion (6 micrograms.kg-1 b. w. h-1) in 30 patients with duodenal ulcer. The drug was administered directly into the gastric lumen. Four different doses were tested: 50 mg (7 patients), 100 mg (6 patients), 150 mg (8 patients), and 200 mg (9 patients). 40749 RP produced a dose-dependent inhibition of maximal acid secretion (p less than 0.001). Fifty per cent inhibition was obtained with a dose of 0.916 mg.kg-1 b. w. corresponding to a dose of 60 mg per day for a patient weighting 65 kg. The inhibitory effect resulted from a decrease in both volumes and H+ concentrations, the influence of the later being prevalent at high dosages. Peptic concentrations were not significantly decreased and inhibition of peptic secretion correlated only with the reduction of volumes. These results showed that 40749 RP is a potent antisecretory drug which could be of benefit in the treatment of peptic ulcer disease. With regard to the duration of action of 40749 RP, a 60 to 100 mg dose administered once a day at bedtime appeared to be optimal regimen for future therapeutic trials.

Adult↗
PubMedDate not supplied

[Ranitidine inhibition of gastric secretion stimulated by pentagastrin. Results in 30 cases of duodenal ulcer].

The aim of this study was to investigate the effects of ranitidine on the pentagastrin stimulated gastric secretion (6 micrograms.kg.h) in 30 patients with duodenal ulcer. The drug was administered directly into the gastric lumen. Five different doses were tested: 15 mg (3 patients), 25 mg (7 patients), 50 mg (6 patients), 75 mg (5 patients), 150 mg (4 patients) and 300 mg (5 patients). Ranitidine produced a dose-dependent inhibition of maximal acid secretion (p less than 0.001). Fifty per cent inhibition was obtained with a dose of 0.342 mg.kg-1 corresponding to a dose of 22 mg for a patient weighing 65 kg. The inhibitory effect resulted from a decrease in both volumes and H+ concentrations, the influence of the later being prevalent at high dosages. A decrease in the peptic secretion has been noticed. For small dosages, it chiefly depends on the reduction of the volumes of gastric secretions, although at high dosages the concentration of pepsin was significantly reduced. These results showed that the ranitidine is a potent antisecretory drug; the dosage of 150 mg twice a day which is considered as the regular treatment for ulcer disease seems adequate. However, the authors suggest that a new controlled therapeutic trial should be started with a dosage of 150 mg per day only, divided in four unequal doses (3 X 25 mg + 75 mg). Furthermore a satisfactory control only of the nocturnal secretion, could be obtained with an unique dose of 100 (or 150) mg at bedtime.

Adult↗